Charles River Laboratories International (CRL) Contributed to Madison Small Cap Fund’s Healthcare Outperformance
Madison Small Cap Fund outperformed benchmarks in Q3 2026, with healthcare and technology sectors driving gains. Charles River Laboratories (CRL) was highlighted as a strong performer, with a 21.18% one-month return. The fund focuses on high-quality companies with strong fundamentals. CRL's stock traded between $146.20 and $357.77 over 52 weeks, closing at $357.35 on October 26, 2026.
How this was made
The 30-second read
Why it matters
The piece provides a qualitative endorsement but no new quantitative data on CRL; its trading relevance is limited.
Market read
The article offers a fund‑level endorsement of CRL, which may generate modest interest but lacks actionable new information.
What to watch
No discussion of upcoming earnings, pipeline updates, or macro headwinds that could affect CRL.
Background
The article summarizes Madison Small Cap Fund's Q3 2026 performance and its top holdings, focusing on Charles River Laboratories as a key contributor.
Ticker impact
Madison Small Cap Fund highlighted a 21.18% one‑month return for Charles River Laboratories (CRL) and cited its strong contribution to the fund's outperformance in Q3 2026.
potential slight upside as investors note strong recent return
The article only repeats fund commentary; no new earnings, guidance, or deal disclosed.
Market effects
Highlights health‑care sector strength in small‑cap space, may boost peer sentiment.
U.S. small‑cap investors may tilt toward health‑care holdings.
Limited; only relevant to U.S. equity investors tracking fund performance.
Counterpoint
Fund praise could be overstated; the stock may already be fully priced in.
Key entities
- companyCharles River Laboratories International
Provider of preclinical and safety assessment services; highlighted for strong recent return.
- investment_fundMadison Small Cap Fund
Small‑cap fund that reported outperformance in Q3 2026.
